Epidermolysis Bullosa Simplex research hub

A 44-week Monocentric Open Study Assessing the Efficacy and Safety of Deucravacitinib in Adults With Inflammatory Genodermatoses

This study is testing a new medicine, deucravacitinib, for adults with specific genetic skin conditions that cause inflammation and blisters or scaly skin. It aims to see how well it works and if it's safe over 44 weeks.